EA7211 STRASS 2 High Risk Retroperitoneal Sarcoma - Clinical Trial
What is the Purpose of this Study?
We are doing this study to compare the usual treatments of surgery alone to using chemotherapy before surgery. We want to know if adding doxorubicin and ifosfamide chemotherapy for liposarcoma (LPS) or doxorubicin and dacarbazine chemotherapy for leiomyosarcoma (LMS) before surgery can improve the long-term survival for patients with these cancers.
High-Risk RetroPeritoneal Sarcoma
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with primary high-risk leiomyosarcoma of retroperitoneal space or infra-peritoneal spaces of pelvis that is either Grade 2 or 3 and has a minimum size of 5 cm; OR
- Are diagnosed with primary high-risk liposarcoma of retroperitoneal space or infra-peritoneal spaces of pelvis that is Grade 2 or 3
- Have unifocal tumor
For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.
What is Involved?
If you choose to join this study, you will be randomly assigned (like a coin flip) to 1 of 2 groups:
If you are assigned to Group 2, you will get 3 cycles of chemotherapy before your surgery. Each chemo cycle lasts 3 weeks. Your surgery will happen 3-6 weeks after your third and final cycle of chemotherapy. The chemotherapy drugs for both LMS and LPS study patients are given as an intravenous infusion (IV, through a vein in your arm) once per week.
Study Details
